Compare NNNN & GSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NNNN | GSBD |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | Germany | United States |
| Employees | 27 | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2013 |
| Metric | NNNN | GSBD |
|---|---|---|
| Price | $31.82 | $8.89 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 14.1K | ★ 1.4M |
| Earning Date | 04-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 13.49% |
| EPS Growth | N/A | ★ 87.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $446.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.58 | $8.65 |
| 52 Week High | $55.65 | $12.03 |
| Indicator | NNNN | GSBD |
|---|---|---|
| Relative Strength Index (RSI) | 59.14 | 37.82 |
| Support Level | $26.31 | N/A |
| Resistance Level | $44.06 | $9.53 |
| Average True Range (ATR) | 2.86 | 0.21 |
| MACD | 0.59 | -0.06 |
| Stochastic Oscillator | 70.78 | 15.36 |
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests in U.S. middle-market companies such as banks and the public debt markets. The company focuses on the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.